RESCAP is under clinical development by Alloksys Life Sciences and currently in Phase II for Burns. According to GlobalData, Phase II drugs for Burns have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RESCAP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RESCAP overview

bRESCAP is bovine alkaline phosphatase derived from bovine intestinal mucosa. It is under development for the treatment of pro-inflammatory post-surgical response in patients undergoing cardiac surgeries aortic valve replacement and coronary artery bypass grafting; acute kidney injury after cardiopulmonary bypass; for preventing ischemia reperfusion injury in living kidney transplantation; reducing systemic inflammatory response syndrome in patients with Sars-CoV-2 infection and wounds. The drug candidate is administered intravenously. It is being developed based on RESCAP platform.
It was under development for the treatment of rheumatoid arthritis as subcutaneous injection.

Alloksys Life Sciences overview

Alloksys Life Sciences (Alloksys) is a biopharmaceutical company that specializes in the development of alkaline phosphatase-based medical treatments for critical care patients. The company’s primarily focuses on the research and development of RESCAP, a proprietary medication based on the enzyme alkaline phosphatase. Alloksys’ therapeutic platform RESCAP is used for preventing adverse downstream complications such as systemic inflammations, issue damage and organ failure during and after major surgery. The company products are primarily used in the healthcare industry, specifically in critical care medicine. Alloksys is headquartered in Wageningen, The Netherlands.

For a complete picture of RESCAP’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.